Physician profile
Aaron Mitchell Sabal
NPI 1780177394
$611.05
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $113 · 2021: $30.95 · 2022: $43.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.31 | 2019-2020 | |
| Pfizer INC. | $172.95 | 2019 | |
| Abbvie INC. | $128.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $25.46 | 2019 | |
| Amgen INC. | $17.58 | 2021 | |
| Mdd US Operations, LLC | $16.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2019 | |
| Gilead Sciences, INC. | $13.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Sabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.